<?xml version="1.0" encoding="UTF-8" standalone="no"?><document id="DDI-DrugBank.d207">
    <sentence id="DDI-DrugBank.d207.s0" text="Substances that are inducers of CYP3A4 activity increase the metabolism of gefitinib and decrease its plasma concentrations.">
        <entity charOffset="75-83" id="DDI-DrugBank.d207.s0.e0" text="gefitinib" type="drug"/>
    </sentence>
    <sentence id="DDI-DrugBank.d207.s1" text="In patients receiving a potent CYP3A4 inducer such as rifampicin or phenytoin, a dose increase to 500 mg daily should be considered in the absence of severe adverse drug reaction, and clinical response and adverse events should be carefully monitored (see CLINICAL PHARMACOLOGY-Pharmacokinetics-Drug-Drug Interactions and DOSAGE AND ADMINISTRATION-Dosage Adjustment sections).">
        <entity charOffset="54-63" id="DDI-DrugBank.d207.s1.e0" text="rifampicin" type="drug"/>
        <entity charOffset="68-76" id="DDI-DrugBank.d207.s1.e1" text="phenytoin" type="drug"/>
        <pair ddi="false" e1="DDI-DrugBank.d207.s1.e0" e2="DDI-DrugBank.d207.s1.e1" id="DDI-DrugBank.d207.s1.p0"/>
    <negationtags>In patients receiving a potent CYP3A4 inducer such as rifampicin or phenytoin, a dose increase to 500 mg daily should be considered in the &lt;scope&gt; &lt;cue&gt; absence of &lt;/cue&gt; severe adverse drug reaction, and clinical response and adverse events should be carefully monitored (see CLINICAL PHARMACOLOGY-Pharmacokinetics-Drug-Drug Interactions and DOSAGE AND ADMINISTRATION-Dosage Adjustment sections). &lt;/scope&gt;</negationtags></sentence>
    <sentence id="DDI-DrugBank.d207.s2" text="International Normalized Ratio (INR) elevations and/or bleeding events have been reported in some patients taking warfarin while on IRESSA therapy.">
        <entity charOffset="114-121" id="DDI-DrugBank.d207.s2.e0" text="warfarin" type="drug"/>
        <entity charOffset="132-137" id="DDI-DrugBank.d207.s2.e1" text="IRESSA" type="brand"/>
        <pair ddi="true" e1="DDI-DrugBank.d207.s2.e0" e2="DDI-DrugBank.d207.s2.e1" id="DDI-DrugBank.d207.s2.p0" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d207.s3" text="Patients taking warfarin should be monitored regularly for changes in prothrombin time or INR.">
        <entity charOffset="16-23" id="DDI-DrugBank.d207.s3.e0" text="warfarin" type="drug"/>
    </sentence>
    <sentence id="DDI-DrugBank.d207.s4" text="Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.">
        <entity charOffset="62-73" id="DDI-DrugBank.d207.s4.e0" text="ketoconazole" type="drug"/>
        <entity charOffset="79-90" id="DDI-DrugBank.d207.s4.e1" text="itraconazole" type="drug"/>
        <entity charOffset="102-110" id="DDI-DrugBank.d207.s4.e2" text="gefitinib" type="drug"/>
        <entity charOffset="136-144" id="DDI-DrugBank.d207.s4.e3" text="gefitinib" type="drug"/>
        <pair ddi="false" e1="DDI-DrugBank.d207.s4.e0" e2="DDI-DrugBank.d207.s4.e1" id="DDI-DrugBank.d207.s4.p0"/>
        <pair ddi="true" e1="DDI-DrugBank.d207.s4.e0" e2="DDI-DrugBank.d207.s4.e2" id="DDI-DrugBank.d207.s4.p1" type="mechanism"/>
        <pair ddi="true" e1="DDI-DrugBank.d207.s4.e0" e2="DDI-DrugBank.d207.s4.e3" id="DDI-DrugBank.d207.s4.p2" type="mechanism"/>
        <pair ddi="true" e1="DDI-DrugBank.d207.s4.e1" e2="DDI-DrugBank.d207.s4.e2" id="DDI-DrugBank.d207.s4.p3" type="mechanism"/>
        <pair ddi="true" e1="DDI-DrugBank.d207.s4.e1" e2="DDI-DrugBank.d207.s4.e3" id="DDI-DrugBank.d207.s4.p4" type="mechanism"/>
        <pair ddi="false" e1="DDI-DrugBank.d207.s4.e2" e2="DDI-DrugBank.d207.s4.e3" id="DDI-DrugBank.d207.s4.p5"/>
    </sentence>
    <sentence id="DDI-DrugBank.d207.s5" text="This increase may be clinically relevant as adverse experiences are related to dose and exposure;"/>
    <sentence id="DDI-DrugBank.d207.s6" text="therefore, caution should be used when administering CYP3A4 inhibitors with IRESSA.">
        <entity charOffset="76-81" id="DDI-DrugBank.d207.s6.e0" text="IRESSA" type="brand"/>
    </sentence>
    <sentence id="DDI-DrugBank.d207.s7" text="Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as ranitidine or cimetidine) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.">
        <entity charOffset="64-96" id="DDI-DrugBank.d207.s7.e0" text="histamine H2-receptor antagonists" type="group"/>
        <entity charOffset="106-115" id="DDI-DrugBank.d207.s7.e1" text="ranitidine" type="drug"/>
        <entity charOffset="120-129" id="DDI-DrugBank.d207.s7.e2" text="cimetidine" type="drug"/>
        <entity charOffset="168-173" id="DDI-DrugBank.d207.s7.e3" text="IRESSA" type="brand"/>
        <pair ddi="false" e1="DDI-DrugBank.d207.s7.e0" e2="DDI-DrugBank.d207.s7.e1" id="DDI-DrugBank.d207.s7.p0"/>
        <pair ddi="false" e1="DDI-DrugBank.d207.s7.e0" e2="DDI-DrugBank.d207.s7.e2" id="DDI-DrugBank.d207.s7.p1"/>
        <pair ddi="true" e1="DDI-DrugBank.d207.s7.e0" e2="DDI-DrugBank.d207.s7.e3" id="DDI-DrugBank.d207.s7.p2" type="mechanism"/>
        <pair ddi="false" e1="DDI-DrugBank.d207.s7.e1" e2="DDI-DrugBank.d207.s7.e2" id="DDI-DrugBank.d207.s7.p3"/>
        <pair ddi="true" e1="DDI-DrugBank.d207.s7.e1" e2="DDI-DrugBank.d207.s7.e3" id="DDI-DrugBank.d207.s7.p4" type="mechanism"/>
        <pair ddi="true" e1="DDI-DrugBank.d207.s7.e2" e2="DDI-DrugBank.d207.s7.e3" id="DDI-DrugBank.d207.s7.p5" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d207.s8" text="Phase II clinical trial data, where IRESSA and vinorelbine have been used concomitantly, indicate that IRESSA may exacerbate the neutropenic effect of vinorelbine.">
        <entity charOffset="36-41" id="DDI-DrugBank.d207.s8.e0" text="IRESSA" type="brand"/>
        <entity charOffset="47-57" id="DDI-DrugBank.d207.s8.e1" text="vinorelbine" type="drug"/>
        <entity charOffset="103-108" id="DDI-DrugBank.d207.s8.e2" text="IRESSA" type="brand"/>
        <entity charOffset="151-161" id="DDI-DrugBank.d207.s8.e3" text="vinorelbine" type="drug"/>
        <pair ddi="false" e1="DDI-DrugBank.d207.s8.e0" e2="DDI-DrugBank.d207.s8.e1" id="DDI-DrugBank.d207.s8.p0"/>
        <pair ddi="false" e1="DDI-DrugBank.d207.s8.e0" e2="DDI-DrugBank.d207.s8.e2" id="DDI-DrugBank.d207.s8.p1"/>
        <pair ddi="false" e1="DDI-DrugBank.d207.s8.e0" e2="DDI-DrugBank.d207.s8.e3" id="DDI-DrugBank.d207.s8.p2"/>
        <pair ddi="false" e1="DDI-DrugBank.d207.s8.e1" e2="DDI-DrugBank.d207.s8.e2" id="DDI-DrugBank.d207.s8.p3"/>
        <pair ddi="false" e1="DDI-DrugBank.d207.s8.e1" e2="DDI-DrugBank.d207.s8.e3" id="DDI-DrugBank.d207.s8.p4"/>
        <pair ddi="true" e1="DDI-DrugBank.d207.s8.e2" e2="DDI-DrugBank.d207.s8.e3" id="DDI-DrugBank.d207.s8.p5" type="effect"/>
    </sentence>
</document>